The role of the CXCL12/CXCR4/CXCR7 chemokine axis in cancer
Chemokines are a family of small, secreted cytokines which regulate a variety of cell
functions. The CXC motif chemokine ligand 12 (CXCL12) binds to CXC chemokine receptor …
functions. The CXC motif chemokine ligand 12 (CXCL12) binds to CXC chemokine receptor …
[HTML][HTML] Cancer stem cell surface markers on normal stem cells
WT Kim, CJ Ryu - BMB reports, 2017 - ncbi.nlm.nih.gov
The cancer stem cell (CSC) hypothesis has captured the attention of many scientists. It is
believed that elimination of CSCs could possibly eradicate the whole cancer. CSC surface …
believed that elimination of CSCs could possibly eradicate the whole cancer. CSC surface …
Cancer stem cells: advances in knowledge and implications for cancer therapy
X Chu, W Tian, J Ning, G Xiao, Y Zhou… - … and Targeted Therapy, 2024 - nature.com
Cancer stem cells (CSCs), a small subset of cells in tumors that are characterized by self-
renewal and continuous proliferation, lead to tumorigenesis, metastasis, and maintain tumor …
renewal and continuous proliferation, lead to tumorigenesis, metastasis, and maintain tumor …
Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies
Abstract Estrogen receptor-positive (ER+) breast cancer accounts for approximately 75% of
all breast cancers. Endocrine therapies, including selective ER modulators (SERMs) …
all breast cancers. Endocrine therapies, including selective ER modulators (SERMs) …
Hypoxia‐inducing factors as master regulators of stemness properties and altered metabolism of cancer‐and metastasis‐initiating cells
M Mimeault, SK Batra - Journal of cellular and molecular …, 2013 - Wiley Online Library
Accumulating lines of experimental evidence have revealed that hypoxia‐inducible factors,
HIF‐1α and HIF‐2α, are key regulators of the adaptation of cancer‐and metastasis‐initiating …
HIF‐1α and HIF‐2α, are key regulators of the adaptation of cancer‐and metastasis‐initiating …
Breast cancer stem cells as drivers of tumor chemoresistance, dormancy and relapse: new challenges and therapeutic opportunities
ML De Angelis, F Francescangeli, A Zeuner - Cancers, 2019 - mdpi.com
Breast cancer is the most frequent cancer among women worldwide. Therapeutic strategies
to prevent or treat metastatic disease are still inadequate although great progress has been …
to prevent or treat metastatic disease are still inadequate although great progress has been …
Emerging targets in cancer management: role of the CXCL12/CXCR4 axis
M Cojoc, C Peitzsch, F Trautmann… - OncoTargets and …, 2013 - Taylor & Francis
The chemokine CXCL12 (SDF-1) and its cell surface receptor CXCR4 were first identified as
regulators of lymphocyte trafficking to the bone marrow. Soon after, the CXCL12/CXCR4 …
regulators of lymphocyte trafficking to the bone marrow. Soon after, the CXCL12/CXCR4 …
Beyond cell motility: the expanding roles of chemokines and their receptors in malignancy
D Morein, N Erlichman, A Ben-Baruch - Frontiers in immunology, 2020 - frontiersin.org
The anti-tumor activities of some members of the chemokine family are often overcome by
the functions of many chemokines that are strongly and causatively linked with increased …
the functions of many chemokines that are strongly and causatively linked with increased …
[HTML][HTML] The role of chemokine receptor CXCR4 in breast cancer metastasis
D Mukherjee, J Zhao - American journal of cancer research, 2013 - ncbi.nlm.nih.gov
Breast cancer is one of the leading causes of cancer related deaths worldwide. Breast
cancer-related mortality is associated with the development of metastatic potential of primary …
cancer-related mortality is associated with the development of metastatic potential of primary …
The breast cancer stem cells traits and drug resistance
Drug resistance is a major challenge in breast cancer (BC) treatment at present.
Accumulating studies indicate that breast cancer stem cells (BCSCs) are responsible for the …
Accumulating studies indicate that breast cancer stem cells (BCSCs) are responsible for the …